Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018.
Cai T et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study. Future Microbiol. 2019 Aug;14:1013-1021. doi: 10.2217/fmb-2019-0145 Abstract
Future Microbiology. Published online: 27 Feb 2017   Urinary tract infections(UTIs) are one of the most common bacterial infections in women, often as a recurrent disease.
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information.
Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194.
For the third consecutive year, Noventure has participated in the annual congress of the EAU - European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world.
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets.
J Gastroint Dig Syst 2012, 2:3.  Abstract:
Future Microbiol. 2017 Oct 25. Abstract: Aim: To compare the protective efficacy of gelatine tannate/probiotic with other antidiarrheal agents in Escherichia coli-inoculated CacoGoblet® cells.